4 documents found, page 1 of 1
Protective efficacy in a hamster model of a multivalent vaccine for human visce...
Fernández, L; Solana, JC; Sánchez, C; Jiménez, MÁ; Requena, JM; Coler, R; Reed, SG; Valenzuela, JG; Kamhawi, S; Oliveira, F; Fichera, E; Glueck, RVisceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if un-treated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the Leishmania membrane protein KMP11, LEISH-F3+ (a recombinant fusion protein, composed of epitopes of the ...
The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs
Lima, C; Santarém, N; Nieto, J; Moreno, J; Carrillo, E; Bartholomeu, D; Bueno, L; Fujiwara, R; Amorim, CMPG; Cordeiro-da-Silva, ACanine leishmaniosis (CanL) prevention in the Mediterranean basin is considered essential to stop human zoonotic visceral leishmaniasis. In this context, vaccination of dogs is expected to have a significant impact in disease control. CaniLeish® (Virbac Animal Health) is one of a few CanL vaccines that are at this moment licensed in Europe. This vaccine contains purified excreted-secreted proteins of Leishmania...
Pre-clinical antigenicity studies of an innovative multivalent vaccine for huma...
Cecílio, P; Pérez-Cabezas, B; Fernández, L.; Moreno, J; Carrillo, E; Requena, J; Fichera, E; Reed, S; Coler, R; Kamhawi, S; Oliveira, F; Valenzuela, JThe notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis...
Interleukin-27 early impacts Leishmania infantum infection in mice and correlat...
Pérez-Cabezas, B; Cecílio, P; Robalo, AL; Silvestre, R; Carrillo, E; Moreno, J; San, Martín J; Vasconcellos, R; Cordeiro-da-Silva, AThe complexity of Leishmania-host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by Leishmania infantum, which returned to basal levels after successful treatment, suggesting this cytokine as a probable infection mediator. We further addressed this hypothesis recurring to two cla...